3118.TWO Level Biotechnology
- Market cap
- TWD 983M
- P/E
- 13.0x
- P/B
- 1.83x
- ROE
- 11.4%
- Dividend yield
- 5.94%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 3118.TWO undervalued?
Graham number3118.TWO trades 2.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Level Biotechnology fundamental analysis
No fundamental analysis for Level Biotechnology yet.
Level Biotechnology stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Level Biotechnology
Level Biotechnology Inc. engages in marketing and distributing cell culture, immunology, and molecular biology products in Taiwan. The company markets and distributes biomedical precision equipment. It also provides services in the areas of mammalian and genetic toxicology, pharmacology, biocompatibility, and model animal production. In addition, it offers preclinical research services to the biotech, pharmaceutical, medical device, animal health, and agrichemical industries…
Full company profileLevel Biotechnology financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Level Biotechnology annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 578M | 629M | 639M | 672M | 677M | 593M | 661M | 731M | 737M | 642M |
| Gross Profit | 208M | 186M | 196M | 212M | 233M | 203M | 220M | 237M | 258M | 229M |
| Operating Income | 80.8M | 49.2M | 56.4M | 73.1M | 85.4M | 73.5M | 79.2M | 75.3M | 83.5M | 63.7M |
| EBITDA | 95.9M | 65.6M | 80.2M | 94.0M | 105M | 93.0M | 98.9M | 103M | 120M | 99.6M |
| Net Income | 68.3M | 38.9M | 47.4M | 58.0M | 68.2M | 58.5M | 62.9M | 64.8M | 79.7M | 61.6M |
| EPS | 2.11 | 1.20 | 1.46 | 1.78 | 2.09 | 1.79 | 1.93 | 2.00 | 2.46 | 1.90 |
| Balance Sheet | ||||||||||
| Total Assets | 732M | 680M | 750M | 773M | 788M | 813M | 823M | 827M | 867M | 799M |
| Total Liabilities | 210M | 182M | 236M | 244M | 243M | 270M | 273M | 267M | 287M | 259M |
| Shareholders' Equity | 522M | 499M | 514M | 529M | 545M | 542M | 549M | 560M | 580M | 540M |
| Cash & Short-term Investments | 321M | 273M | 344M | 380M | 473M | 463M | 467M | 253M | 210M | 195M |
| Total Debt | - | - | - | 15.9M | 13.4M | 12.7M | 13.5M | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 71.3M | 26.8M | 109M | 83.2M | 156M | 65.1M | 70.2M | 64.1M | 59.6M | 117M |
| Capital Expenditure | 10.8M | 2.51M | 2.43M | 2.54M | 9.16M | 6.74M | 7.67M | 224M | 32.7M | 1.33M |
| Free Cash Flow | 62.5M | 24.3M | 107M | 80.7M | 147M | 58.3M | 62.5M | -160M | 26.9M | 116M |
| Ratios | ||||||||||
| ROE | 13.1% | 7.8% | 9.2% | 11.0% | 12.5% | 10.8% | 11.4% | 11.6% | 13.7% | 11.4% |
| ROA | 9.3% | 5.7% | 6.3% | 7.5% | 8.7% | 7.2% | 7.6% | 7.8% | 9.2% | 7.7% |
| Net Profit Margin | 11.8% | 6.2% | 7.4% | 8.6% | 10.1% | 9.9% | 9.5% | 8.9% | 10.8% | 9.6% |
| Debt to Equity | - | - | - | 0.03x | 0.02x | 0.02x | 0.02x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Level Biotechnology dividends
- Dividend yield
- 5.94%
- Forward dividend
- 2.20 TWD
- Payout ratio
- 73.3%
- Ex-dividend date
- Jun 10, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 58.4M | 1.80 | 73.3% |
| 2024 | TWD 55.2M | 1.70 | 85.1% |
| 2023 | TWD 55.2M | 1.69 | 87.7% |
| 2022 | TWD 61.7M | 1.89 | 105.5% |
| 2021 | TWD 51.9M | 1.59 | 76.2% |
| 2020 | TWD 42.2M | 1.29 | 72.7% |
| 2019 | TWD 32.5M | 1.00 | 68.5% |
| 2018 | TWD 61.7M | 1.90 | 158.5% |
| 2017 | TWD 61.7M | 1.90 | 90.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.05:1 on Aug 5, 2011.
Who owns Level Biotechnology
- Insiders 32.60%
- Institutions 0.00%
- Public & others 67.41%
- Shares outstanding 32.5M
- Free float 21.7M
Level Biotechnology company profile
- Company name
- Level Biotechnology
- Ticker
- 3118.TWO
- ISIN
- TW0003118006
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 128
- Fiscal year end
- December
- Address
- No. 80, Kangning Street, New Taipei City, Taiwan, 221
- Phone
- 886 2 2695 9935
- Website
- level.com.tw
About Level Biotechnology
Level Biotechnology Inc. engages in marketing and distributing cell culture, immunology, and molecular biology products in Taiwan. The company markets and distributes biomedical precision equipment. It also provides services in the areas of mammalian and genetic toxicology, pharmacology, biocompatibility, and model animal production. In addition, it offers preclinical research services to the biotech, pharmaceutical, medical device, animal health, and agrichemical industries. The company was founded in 1989 and is headquartered in New Taipei City, Taiwan.
Level Biotechnology management
2- Jia-Xian YeManager
- Yihan LiAccounting Supervisor